A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
收藏DataCite Commons2026-01-28 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012698/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
提供机构：
Vivli
创建时间：
2026-01-28
